Home » Stocks » ALRN

Aileron Therapeutics, Inc. (ALRN)

Stock Price: $1.01 USD -0.01 (-0.50%)
Updated Aug 3, 2021 12:11 PM EDT - Market open
Market Cap 93.04M
Revenue (ttm) n/a
Net Income (ttm) -21.38M
Shares Out 90.33M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $1.01
Previous Close $1.01
Change ($) -0.01
Change (%) -0.50%
Day's Open 1.01
Day's Range 1.00 - 1.01
Day's Volume 108,811
52-Week Range 0.91 - 2.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients,...

3 weeks ago - GlobeNewsWire

Aileron Therapeutics Inc (NASDAQ: ALRN) has initiated Phase 1b trial of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer undergoing chemotherapy.  Aileron plans to ...

1 month ago - Benzinga

BOSTON, June 24, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients,...

1 month ago - GlobeNewsWire

-- Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held on  Wednesday, May 26, 2021 at 11:00 am ET -- -- Featured speakers will include hematologist Alan List, M.D. and  geriatric...

2 months ago - GlobeNewsWire

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Other stocks mentioned: ALNA, MBIO, MCHX, MDWD, OBSV, RWLK
5 months ago - InvestorPlace

-- Several existing Aileron investors, including Satter Medical Technology Partners  and Lincoln Park Capital Fund, LLC, also participated in the offering -- – Aileron plans to use net proceeds to under...

6 months ago - GlobeNewsWire

WATERTOWN, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (Nasdaq: ALRN), today announced that it has entered into definitive agreements with fundamental healthcare investors for th...

6 months ago - GlobeNewsWire

As with many biopharma names, there's volatility and risk in ALRN stock. This firm is seeking to reduce the effects of chemotherapy.

6 months ago - InvestorPlace

WATERTOWN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the third quarter ended September 30, 2020.

8 months ago - GlobeNewsWire

WATERTOWN, Mass., Oct. 24, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced new positive clinical data from its ongoing Phase 1b trial demonstrating clinical proof of concept...

9 months ago - GlobeNewsWire

WATERTOWN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b proof-of-c...

9 months ago - GlobeNewsWire

Aileron Therapeutics (ALRN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that proof-of-concept data from the company’s Phase 1b study of ALRN-6924 will be featured in a la...

9 months ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (NASDAQ: ALRN), today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $...

10 months ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate pr...

10 months ago - GlobeNewsWire

Here we discuss five biotech companies recording impressive growth so far in 2020.

Other stocks mentioned: CLDX, EBS, HZNP, NVAX
11 months ago - Zacks Investment Research

WATERTOWN, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the second quarter ended June 30, 2020.

11 months ago - GlobeNewsWire

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two u...

1 year ago - GlobeNewsWire

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today that it has completed enrollment in the dose optimization expansion cohort of its ongoing open-la...

1 year ago - GlobeNewsWire

 -- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy’s off-target effects --  – In p5...

1 year ago - GlobeNewsWire

WATERTOWN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by t...

1 year ago - GlobeNewsWire

WATERTOWN, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a publ...

1 year ago - GlobeNewsWire

WATERTOWN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron als...

1 year ago - GlobeNewsWire

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

Other stocks mentioned: CBAY, EFOI, MRSN, MVIS
1 year ago - Zacks Investment Research

WATERTOWN, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical t...

1 year ago - GlobeNewsWire

Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients - - - Scheduled to report interim results from ...

1 year ago - GlobeNewsWire

Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study - - -  Final data readout from Phase 1b for both dose optimization and schedule optimization in...

1 year ago - GlobeNewsWire

WATERTOWN, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides, announced today the promotion o...

1 year ago - GlobeNewsWire

Aileron Therapeutics, Inc. (ALRN) CEO Manuel Aivado on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Nonclinical research results show that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells and enhanced the anti-cancer activity of chemotherapy

1 year ago - GlobeNewsWire

Nonclinical research showed that ALRN-6924 prevented the toxic side effects of chemotherapy in normal cells without inhibiting the anti-cancer activity of chemotherapy.

1 year ago - GlobeNewsWire

Treatment uses a precision-medicine strategy to prevent the toxic side-effects of chemotherapy in patients with p53-mutated cancer, representing approximately 50% of all patients with cancer.

1 year ago - GlobeNewsWire

Final data expected in the second quarter of 2020 Final data expected in the second quarter of 2020

1 year ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer patients, today ...

1 year ago - GlobeNewsWire

WATERTOWN, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating peptides to treat cancer and other diseas...

1 year ago - GlobeNewsWire

About ALRN

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in pa... [Read more...]

Industry
Biotechnology
IPO Date
Jun 29, 2017
Stock Exchange
NASDAQ
Ticker Symbol
ALRN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ALRN stock is "Strong Buy." The 12-month stock price forecast is 3.50, which is an increase of 248.26% from the latest price.

Price Target
$3.50
(248.26% upside)
Analyst Consensus: Strong Buy